Spitalul Clinic Municipal Filantropia Craiova

Craiova 200508

1 studies enrolling now · 9 studies all time

What they study most

Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia (for Part B and C), Healthy (For Part A), Hypertension, Leukemia, Lymphoma, Non-Hodgkin, Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL), Post-Essential Thrombocythemia MF (Post-ET-MF), Post-Polycythemia Vera MF (Post-PV-MF), Primary Myelofibrosis (PMF), Refractory Multiple Myeloma

Studies at this site

• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia — Running, not enrolling
• Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies — Stopped early
• Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension — Completed
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. — Completed
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) — Stopped early
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) — Completed
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed